Johnson & Johnson Vision wins Fast Company award for drug-eluting contact lens

[Image from Johnson & Johnson Vision]Johnson & Johnson Vision announced today that it was named a winner of Fast Company’s 2022 World Changing Ideas Awards.

The eye health business arm of Johnson & Johnson (NYSE: JNJ) received the award in the “Wellness” category for its Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen). The drug-eluting contact, which provides a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction, received FDA approval in March.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market

[Image from Johnson & Johnson Vision] Johnson & Johnson has a potential alternative to eye drops with its drug-eluting Acuvue Theravision contact lens.

As far back as the early 1960s, researchers toyed with the idea of delivering medication through contact lenses.

Johnson & Johnson Vision (NYSE:JNJ) Director of Clinica Science Dr. Brian Pall told Drug Delivery Business News that patents back then disclosed how a soft contact lens of hydrogel material could be an effective vehicle for delivering medication to the eye.

On March 2, well over half a century since the notion was floated, Johnson & Johnson announced that the FDA approved its Acuvue Theravision with Ketotifen, making it the first drug-eluting contact lens authorized for marketing in the U.S. Having already been approved in Japan and Canada, Pall said it is the world’s first contact lens of its kind.

“[Eye drops] are just not a super-efficient way to deliver medication to a targe…

Read more
  • 0

FDA approves Johnson & Johnson Vision’s drug-eluting contact lens

Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Theravision with Ketotifen.

The eye health business arm of Johnson & Johnson (NYSE:JNJ) designed Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen) to provide a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

J&J launches Veritas Vision System for cataract surgery

J&J Vision today announced that it has launched its Veritas Vision System for cataract surgery.

Santa Ana, Calif.-based J&J designed the phacoemulsification system to address patient safety, surgeon efficiency and comfort. Phacoemulsification is the gold standard treatment during cataract surgery and allows surgeons to effectively emulsify and efficiently remove the eye’s internal lens, according to the company.

“In my experience, the advancements in fluidics management and usability of the Veritas Vision System have made a marked improvement in safety and stability of the phaco procedure,” Jason Jones a doctor at Jones Eye Clinic in Sioux City, Iowa, said in a news release. “I’ve found I can glide through any lens density with less surge, and the level of chamber stability I’ve experienced with Veritas gives me more confidence to take advantage of Venturi mode, the more powerful phaco setting.”

The Verit…

Read more
  • 0

FDA approves J&J Vision’s overnight contact lens for myopia management

Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Abiliti overnight therapeutic lenses.

Jacksonville, Fla.-based J&J Vision touts the Acuvue Abiliti as the first and only FDA-approved orthokeratology (ortho-k) contact lens for managing myopia, according to a news release.

The company designed the Abiliti overnight ortho-k lenses to be fitted to match the eye based on its unique corneal shape and temporarily reshape the cornea. The technology uses corneal topography, refractive error and other measurements connected to the fitting software, which is user-friendly and provides a precise measurement of the corneal shape while accurately guiding the eye care professional through the fitting process.

Abiliti overnight lenses will be available in two forms — basic overnight therapeutic lenses and overnight therapeutic lenses for astigmatism, J&J Vision said. The company expects the lenses to be available in the U…

Read more
  • 0

Canada approves J&J Vision’s drug-eluting contact lens

Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens.

Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

J&J Vision wins regulatory nods for phacoemulsification machine

Johnson & Johnson Vision (NYSE:JNJ) announced today that it received FDA 510(k) clearance and CE mark for its Veritas vision system.

Santa Ana, Calif.–based Johnson & Johnson Vision’s next-generation Veritas phacoemulsification system is designed to allow surgeons to guide through any lens density with less surge and more stability. It also incorporates advancements in ergonomics to enhance usability during cataract surgery, according to a news release.

Veritas’ approvals in the U.S. and Europe follow recent FDA nods for J&J Vision’s Tecnis Eyhance and Tecnis Eyhance Toric II intraocular lens for treating cataract patients, the company said.

Johnson & Johnson Vision intends to begin the full commercial launch of the Veritas system around the globe later this year, the company said.

“While the phacoemulsification technique has been used successfully for decades, ease of use continues to be the unmet need wi…

Read more
  • 0

J&J Vision, Menicon to collaborate on therapeutic contact lens

Johnson & Johnson (NYSE:JNJ) Vision announced today that it entered into a strategic collaboration with Menicon for contact lens development.

J&J Vision and Menicon are partnering to bring forward a novel portfolio of products and services to manage the progression of myopia, sometimes known as “nearsightedness,” in children, according to a news release.

Menicon is set to manufacture therapeutic contact lenses designed to help manage the progression of myopia in children, while J&J Vision will be responsible for expanding the availability of the lenses around the world.

“For decades, Johnson & Johnson Vision has invested in research collaborations with academic centers, research institutes and leading global health organizations who share our vision of leading with science to reshape the future of myopia and eye health,” J&J Vision Care global president Peter Menziuso said in the release. “Our collaboration with Menicon ma…

Read more
  • 0